The fine specificity of IgM anti-citrullinated protein antibodies (ACPA) is different from that of IgG ACPA

Arthritis Research and Therapy

Volumn 13, Issue 6, 2011, Pages

  Suwannalai, Parawee ^a   Willemze, Annemiek ^a   van Toorn, Linda ^a   Stoeken Rijsbergen, Gerrie ^a   Levarht, Nivine ^a   Drijfhout, Jan W ^a   J Huizinga, Tom W ^a   M Toes, Rene E ^a   Trouw, Leendert A ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; ENOLASE; FIBRINOGEN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MYELIN BASIC PROTEIN; VIMENTIN; CYCLIC CITRULLINATED PEPTIDE; CYCLOPEPTIDE; EPITOPE;

ANTIBODY BLOOD LEVEL; ANTIBODY SPECIFICITY; ANTIGEN RECOGNITION; ARTICLE; B LYMPHOCYTE; CLINICAL ASSESSMENT; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MAJOR CLINICAL STUDY; RHEUMATOID ARTHRITIS; AMINO ACID SEQUENCE; BLOOD; IMMUNOLOGY; MOLECULAR GENETICS; PROTEIN STABILITY; TIME;

AMINO ACID SEQUENCE; ANTIBODY SPECIFICITY; ARTHRITIS, RHEUMATOID; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; FIBRINOGEN; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MOLECULAR SEQUENCE DATA; MYELIN BASIC PROTEIN; PEPTIDES, CYCLIC; PHOSPHOPYRUVATE HYDRATASE; PROTEIN STABILITY; TIME FACTORS; VIMENTIN;

EID: 82255167645     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3524     Document Type: Article

References (18)

1. van Venrooij WJ, Hazes JM, Visser H. Anticitrullinated protein/peptide antibody and its role in the diagnosis and prognosis of early rheumatoid arthritis. Neth J Med 2002, 60:383-388.
2. Nielen MM, van der Horst AR, van Schaardenburg D, van der Horst-Bruinsma IE, van de Stadt RJ, Aarden L, Dijkmans BA, Hamann D. Antibodies to citrullinated human fibrinogen (ACF) have diagnostic and prognostic value in early arthritis. Ann Rheum Dis 2005, 64:1199-1204. 10.1136/ard.2004.029389, 1755615, 15640269.
3. Lindqvist E, Eberhardt K, Bendtzen K, Heinegård D, Saxne T. Prognostic laboratory markers of joint damage in rheumatoid arthritis. Ann Rheum Dis 2005, 64:196-201. 10.1136/ard.2003.019992, 1755350, 15458956.
4. Clavel C, Nogueira L, Laurent L, Iobagiu C, Vincent C, Sebbag M, Serre G. Induction of macrophage secretion of tumor necrosis factor α through Fcγ receptor IIa engagement by rheumatoid arthritis-specific autoantibodies to citrullinated proteins complexed with fibrinogen. Arthritis Rheum 2008, 58:678-688. 10.1002/art.23284, 18311806.
5. Schuerwegh AJ, Ioan-Facsinay A, Dorjée AL, Roos J, Bajema IM, van der Voort EI, Huizinga TW, Toes RE. Evidence for a functional role of IgE anticitrullinated protein antibodies in rheumatoid arthritis. Proc Natl Acad Sci USA 2010, 107:2586-2591. 10.1073/pnas.0913054107, 2823893, 20133791.
6. Trouw LA, Haisma EM, Levarht EW, van der Woude D, Ioan-Facsinay A, Daha MR, Huizinga TW, Toes RE. Anti-cyclic citrullinated peptide antibodies from rheumatoid arthritis patients activate complement via both the classical and alternative pathways. Arthritis Rheum 2009, 60:1923-1931. 10.1002/art.24622, 19565507.
7. Kroczek RA, Graf D, Brugnoni D, Giliani S, Korthüer U, Ugazio A, Senger G, Mages HW, Villa A, Notarangelo LD. Defective expression of T-cell CD40 ligand causes X-linked immunodeficiency with hyper-IgM. Nature 1993, 361:539-541. 10.1038/361539a0, 7679206.
8. Verpoort KN, Jol-van der Zijde CM, Papendrecht-van der Voort EA, Ioan-Facsinay A, Drijfhout JW, van Tol MJ, Breedveld FC, Huizinga TW, Toes RE. Isotype distribution of anti-cyclic citrullinated peptide antibodies in undifferentiated arthritis and rheumatoid arthritis reflects an ongoing immune response. Arthritis Rheum 2006, 54:3799-3808. 10.1002/art.22279, 17133560.
9. Rajewsky K. Clonal selection and learning in the antibody system. Nature 1996, 381:751-758. 10.1038/381751a0, 8657279.
10. Racine R, McLaughlin M, Jones DD, Wittmer ST, MacNamara KC, Woodland DL, Winslow GM. IgM production by bone marrow plasmablasts contributes to long-term protection against intracellular bacterial infection. J Immunol 2011, 186:1011-1021. 10.4049/jimmunol.1002836, 21148037.
11. van Aken J, van Dongen H, le Cessie S, Allaart CF, Breedveld FC, Huizinga TW. Comparison of long term outcome of patients with rheumatoid arthritis presenting with undifferentiated arthritis or with rheumatoid arthritis: an observational cohort study. Ann Rheum Dis 2006, 65:20-25. 10.1136/ard.2005.038471, 1797989, 15901632.
12. Verpoort KN, Cheung K, Ioan-Facsinay A, van der Helm-van Mil AH, de Vries-Bouwstra JK, Allaart CF, Drijfhout JW, de Vries RR, Breedveld FC, Huizinga TW, Pruijn GJ, Toes RE. Fine specificity of the anti-citrullinated protein antibody response is influenced by the shared epitope alleles. Arthritis Rheum 2007, 56:3949-3952. 10.1002/art.23127, 18050209.
13. Boire G, Cossette P, de Brum-Fernandes AJ, Liang P, Niyonsenga T, Zhou ZJ, Carrier N, Daniel C, Ménard HA. Anti-Sa antibodies and antibodies against cyclic citrullinated peptide are not equivalent as predictors of severe outcomes in patients with recent-onset polyarthritis. Arthritis Res Ther 2005, 7:R592-R603. 10.1186/ar1719, 1174957, 15899046.
14. Bernasconi NL, Traggiai E, Lanzavecchia A. Maintenance of serological memory by polyclonal activation of human memory B cells. Science 2002, 298:2199-2202. 10.1126/science.1076071, 12481138.
15. Ioan-Facsinay A, el-Bannoudi H, Scherer HU, van der Woude D, Ménard HA, Lora M, Trouw LA, Huizinga TW, Toes RE. Anti-cyclic citrullinated peptide antibodies are a collection of anti-citrullinated protein antibodies and contain overlapping and non-overlapping reactivities. Ann Rheum Dis 2011, 70:188-193. 10.1136/ard.2010.131102, 20736390.
16. Snir O, Widhe M, von Spee C, Lindberg J, Padyukov L, Lundberg K, Engström A, Venables PJ, Lundeberg J, Holmdahl R, Klareskog L, Malmström V. Multiple antibody reactivities to citrullinated antigens in sera from patients with rheumatoid arthritis: association with HLA-DRB1 alleles. Ann Rheum Dis 2009, 68:736-743. 10.1136/ard.2008.091355, 18635594.
17. Kumpel BM. In vivo studies of monoclonal anti-D and the mechanism of immune suppression. Transfus Clin Biol 2002, 9:9-14. 10.1016/S1246-7820(01)00209-9, 11889904.
18. Suwannalai P, Scherer HU, van der Woude D, Ioan-Facsinay A, Jol-van der Zijde CM, van Tol MJ, Drijfhout JW, Huizinga TW, Toes RE, Trouw LA. Anti-citrullinated protein antibodies have a low avidity compared with antibodies against recall antigens. Ann Rheum Dis 2011, 70:373-379. 10.1136/ard.2010.135509, 21068094.